. Author manuscript; available in PMC: 2012 Dec 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2011 Oct 17;17(12):1725–1738. doi: 10.1016/j.bbmt.2011.10.006

Table 3.

Studies of Low Bone Mineral Density (BMD) Following Pediatric HCT^*

	Reference	Number	Disease	Age at HCT (years)	Age at Study (years)	F/U Median (range)	Z-score		Z-score −1 to −2	Z-score <−2
	Reference	Number	Disease	Age at HCT (years)	Age at Study (years)	F/U Median (range)	Total body	Lumbar	Z-score −1 to −2	Z-score <−2
Bhatia et al. 1998	30	10	AML, CML	5.0^Mdn (3.0–18.0)	12.0^Mdn (4.0–22.0)	2.0 yrs^Mdn (1.0–10.0)	−0.5^Mdn (−2.0 to 1.0)	NR	NR	NR
Nysom et al. 2000	31	25	ALL, AML, CML, NHL	11.3^Mdn (5.7–17.6)	17.2^Mdn (11.3–26.5)	7.5 yrs^Mdn (3.6–12.6)	−0.5^M	−0.5^M	NR	NR
Daniels et al. 2003	32	15	Varied	NR	15.2^M (9.4–17.7)	6.3 yrs^M (1.0–12.2)	−0.7 to −0.9^M	−0.7 to −0.9^M	NR	NR
Kaste et al. 2004	33	43	Varied	10.3^Mdn (1.6–20.4)	15.8^Mdn (4.4–27.2)	5.1 yrs^Mdn (1.0–10.2)	NR	−0.9^{Mdn,^} (−3.3 to 2.3)	26%	21%
Petryk et al. 2006	29	21	Varied	10.2^M (5.1–17.9)	10.2^M (5.1–17.9)	≤1.0 yrs	NR	−0.9^M (−2.9 to 1.1)	33%	19%
Perkins et al. 2007	34	17	ALL, AML	1.7^M (0.6–3.0)	13.2^M (3.8–23.8)	11.6 yrs^M (3.3–22.3)	NR	−0.3^M (−2.4 to 2.0)	18%	6%
Carpenter et al. 2007	35	66	ALL, others	(1.1–17.9)	(2.0–18.2)	NR	NR	−3.6 to −2.5^Mdn (−5.2 to −0.9)	NR	NR

Studies without data on lumbar and/or total body BMD were excluded

ALL Acute Lymphoblastic Leukemia

AML Acute Myeloblastic Leukemia

CML Chronic Myelogenous Leukemia

MDS Myelodysplastic Syndrome

NHL Non-Hodgkins Lymphoma

^{^} by QCT

^Mmean

^Mdnmedian

NR Not Reported